Cikakken Bayani na Maganin Cutar sankarar bargo
Alamun CAR-T
●B-cell m lymphoblastic cutar sankarar bargo
●Multiple myeloma
●Cutar sankarar lymphocytic na yau da kullun
●Non-Hodgkin lymphoma
●Yada manyan B-cell lymphoma
●SLE (Systemic Lupus Erythematosus)
●Myasthenia gravis
●Sauran cututtuka na autoimmune
Kyakkyawan aikin CAR-T na asibiti
Alamun CD19+20CAR-T:Marasa lafiya tare da lymphoma na B-cell ba Hodgkin
Farashin CR na wata daya | Ƙimar PR na wata ɗaya | Watan KO ƙimar | CRS≥3 | CRES≥3 |
71.95% (59/82) | 25.6 (21/82) | 97.55 (80/82) | 12.19% (10/82) | 0 |
Alamun CD19+22CAR-T:Jiyya na CD19 relapsed da refractory m B-lymphocytic cutar sankarar bargo marasa lafiya
Farashin CR na wata daya | Ƙimar PR na wata ɗaya | Watan KO ƙimar | CRS≥3 | CRES≥3 |
92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Alamomi ga BCMACAR-T:Magani na sake dawowa da kuma refractory mahara myeloma
Farashin CR na wata daya | Ƙimar PR na wata ɗaya | Watan KO ƙimar | CRS≥3 | CRES≥3 |
72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Amfaninmu
● Magani Na Musamman: Kowane magani na CAR-T an keɓance shi ga mai haƙuri, yana tabbatar da sakamako mai mahimmanci da tasiri.
● Zaɓuɓɓukan Nuna Daban-daban: Tare da nau'o'in antigens masu yawa, ciki har da CD7, CD19, CD20, CD22, da BCMA, samfuranmu na CAR-T suna ba da damar da ba za a iya kwatanta su ba wajen magance cututtuka daban-daban na hematological da cututtuka na autoimmune.
● Tabbatar da Nasarar Clinical: Hanyoyin mu na CAR-T sun nuna tasiri na musamman a cikin lokuta masu yawa na asibiti, tare da ƙimar gafara mai ban sha'awa da bayanan martaba, ƙarfafa matsayinmu a matsayin jagora a immunotherapy.
● Babban Kuɗi-Tasiri: Muna ba da fa'ida mai fa'ida tare da ingantattun jiyya masu inganci a ƙarin farashi mai sauƙi idan aka kwatanta da sauran samfuran CAR-T akan kasuwa.
● Fasahar Yanke-Edge: Yin amfani da sabbin ci gaba a aikin injiniyan kwayoyin halitta, hanyoyin mu na CAR-T sun haɗa da makomar ciwon daji da kuma maganin cututtuka na autoimmune.
● Ƙwararrun Taimakon Asibiti: Teamungiyarmu ta ƙwararrun likitocinmu da masu bincike suna ba da cikakkiyar kulawa daga takara na farko ta hanyar yin bijirewa.
Kwayoyin CAR-T yanzu an san su sosai don ingancin su a cikin marasa lafiya waɗanda ba su amsa maganin gargajiya kamar chemotherapy ko dashen kasusuwa ba. Ƙungiyar likitocin duniya sun yarda da yuwuwar haɓakar fasahar CAR-T wajen sauya sakamakon haƙuri.
bayanin 2